Afobazol is the anxiolytic with fabomotizole — a selective anxiolytic with a fundamentally different mechanism than benzodiazepines: it acts as a sigma-1 receptor agonist and restores the sensitivity of GABA/benzodiazepine receptors under stress conditions, without binding them directly. The practical result is anxiety relief without sedation, without muscle relaxation, without cognitive impairment — and without the dependence and withdrawal syndrome that defines benzodiazepines. In countries where it is registered, Afobazol is used for anxiety states, stress reactions and adaptation disorders in adults — including patients who cannot take or do not want sedating anxiolytics.
Afobazol is used (per registered indications and physician guidance) for:
Important: fabomotizole is not an antipsychotic or antidepressant — for clinical depression, severe anxiety disorders or panic disorder, prescription psychiatric therapy is required. Afobazol addresses the milder anxiety spectrum.
No — the mechanism is entirely different. Benzodiazepines directly enhance GABA inhibition (causing sedation, dependence and withdrawal); fabomotizole acts on sigma-1 receptors and modulates stress-response systems without direct GABA binding. The result: anxiety relief without the sedation, cognitive dulling and dependence that define benzodiazepines. It is closer to "stress-adaptation support" than to classic tranquilizers.
Not immediately — this is the key expectation to set. Unlike benzodiazepines that work in minutes, fabomotizole builds its effect over 2–4 weeks of daily use: anxiety intensity typically decreases gradually, with irritability and tension softening first. Judge the result after a full 4-week course, not after the first tablet.
Yes — the absence of sedation is one of its defining features. Unlike benzodiazepines, fabomotizole does not slow reaction time or dull concentration in standard studies. Individual sensitivity varies, so observe your own response during the first days, but daytime functioning is generally preserved.
Inform your physician about everything you take. Fabomotizole does not have the dangerous alcohol/depressant synergy of benzodiazepines, but combinations with other anxiolytics, antidepressants or sedatives should still be physician-reviewed. It is often used alongside psychotherapy — a combination that works well.
Afobazol addresses the mild-to-moderate anxiety spectrum and adaptation stress. Clinical depression, panic disorder, generalized anxiety disorder of significant severity require prescription psychiatric therapy — SSRI/SNRI medicines, psychotherapy, or both. Self-treating severe conditions with an OTC anxiolytic delays proper care. See a physician honestly about your symptoms.
Ask a question or inquire about delivery to your country
